浏览全部资源
扫码关注微信
1.郑州中医骨伤病医院,郑州 450016
2.河南省中医院,郑州 450000
Received:29 May 2022,
Published Online:10 October 2022,
Published:20 June 2023
移动端阅览
周志锋,郭会卿,崔朋涛等.湿热痹清丸治疗类风湿关节炎湿热痹阻证的临床观察及对OPG/RANKL/RANK通路和TNF-α的影响[J].中国实验方剂学杂志,2023,29(12):121-127.
ZHOU Zhifeng,GUO Huiqing,CUI Pengtao,et al.Shire Biqing Pill in Treatment of Rheumatoid Arthritis with Damp-heat Obstruction Syndrome and Its Effect on OPG/RANKL/RANK Signaling Pathway and TNF-α[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(12):121-127.
周志锋,郭会卿,崔朋涛等.湿热痹清丸治疗类风湿关节炎湿热痹阻证的临床观察及对OPG/RANKL/RANK通路和TNF-α的影响[J].中国实验方剂学杂志,2023,29(12):121-127. DOI: 10.13422/j.cnki.syfjx.202202321.
ZHOU Zhifeng,GUO Huiqing,CUI Pengtao,et al.Shire Biqing Pill in Treatment of Rheumatoid Arthritis with Damp-heat Obstruction Syndrome and Its Effect on OPG/RANKL/RANK Signaling Pathway and TNF-α[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(12):121-127. DOI: 10.13422/j.cnki.syfjx.202202321.
目的
2
通过研究湿热痹清丸治疗类风湿关节炎湿热痹阻证的临床疗效及对患者血清骨保护素(OPG)、核转录因子-
κ
B受体活化因子配体(RANKL)、肿瘤坏死因子-
α
(TNF-
α
)表达的影响,从骨破坏的角度探讨其作用机制。
方法
2
采用随机数字表法将纳入的类风湿关节炎湿热痹阻证患者分为两组,每组各36例患者。对照组给予口服甲氨蝶呤片、塞来昔布胶囊治疗;治疗组在对照组的基础上配合口服中成药湿热痹清丸治疗,其治疗周期为3个月。分别记录治疗前和治疗后疼痛视觉模拟(VAS)评分、关节压痛数、关节肿胀数、疾病活动度评分(DAS28-ESR)、中医症状量化积分及相关不良反应并检测外周血清OPG、RANKL、TNF-
α
、红细胞沉降率(ESR)、C反应蛋白(CRP)水平。
结果
2
治疗后,治疗组总有效率为88.57%(31/35),对照组总有效率为79.41%(27/34),治疗组总有效率高于对照组(
Z
=-2.089,
P
<
0.05)。与本组治疗前比较,两组疼痛VAS评分、关节压痛数、关节肿胀数及DAS28-ESR均明显降低(
P
<
0.05);治疗后与对照组比较,治疗组疼痛VAS评分、关节压痛数、关节肿胀数及DAS28-ESR改善更明显(
P
<
0.05)。与本组治疗前比较,两组中医症状量化积分明显降低(
P
<
0.05);治疗后与对照组比较,治疗组中医症状量化积分降低更明显(
P
<
0.05)。与本组治疗前比较,两组RANKL、TNF-
α、
ESR、CRP水平均明显降低,OPG水平明显升高(
P
<
0.05);治疗后与对照组比较,治疗组RANKL、TNF-
α、
ESR、CRP水平降低更明显,OPG水平升高更明显(
P
<
0.05)。在本次临床试验期间未出现任何严重不良事件及严重不良反应。
结论
2
湿热痹清丸可以有效改善湿热痹阻型类风湿关节炎患者的临床症状,有较好的安全性;湿热痹清丸可以有效调控OPG/RANKL/RANK系统,同时降低促炎因子TNF-
α
,这有可能是其干预RA骨破坏的作用机制。
Objective
2
To study the clinical efficacy of Shire Biqing pill in the treatment of rheumatoid arthritis (damp-heat obstruction syndrome) and its effect on the expression of serum osteoprotegerin (OPG), nuclear factor-
κ
B receptor activating factor ligand (RANKL), and tumor necrosis factor-
α
(TNF-
α
), and to explore its mechanism from the perspective of bone destruction.
Method
2
Patients with rheumatoid arthritis (damp-heat obstruction syndrome) were randomly divided into two groups, with 36 patients in each group. The control group was treated with methotrexate tablets and celecoxib capsule, while the treatment group was treated with Shire Biqing pill based on the control group. The treatment period was 3 months. The pain visual analogue scale (VAS) score, joint tenderness number, joint swelling number, disease activity score (DAS28-ESR), traditional Chinese medicine (TCM) symptom quantitative score, and related adverse reactions were recorded before and after treatment, and the peripheral serum OPG, RANKL, TNF-
α
, erythrocyte sedimentation rate (ESR), and Creactive protein (CRP) were detected.
Result
2
After treatment, the total effective rate was 88.57% (31/35) in the treatment group and 79.41% (27/34) in the control group. The total effective rate of the treatment group was higher than that of the control group (
Z
=-2.089,
P
<
0.05). The pain VAS score, joint tenderness number, joint swelling number, and DAS28-ESR of the two groups were significantly lower than those before treatment (
P
<
0.05), and the pain VAS score, joint tenderness number, joint swelling number, and DAS28-ESR of the treatment group were significantly better than those of the control group after treatment (
P
<
0.05). Compared with that before treatment, the TCM symptom quantitative score in the two groups decreased significantly (
P
<
0.05), and the decrease was more obvious in the treatment group than in the control group (
P
<
0.05). Compared with those before treatment, the levels of RANKL, TNF-
α
, ESR, and CRP in the two groups decreased and the level of OPG increased (
P
<
0.05), and the changes in the treatment group were more obvious that in the control group (
P
<
0.05). There were no serious adverse events or serious adverse reactions during this clinical trial.
Conclusion
2
Shire Biqing pill can effectively improve the clinical symptoms of rheumatoid arthritis (damp-heat obstruction syndrome) with good safety. Shire Biqing pill effectively regulate the OPG/RANKL/RANK system and reduce the pro-inflammatory factor TNF-
α
, which may be its mechanism in the intervention in rheumatoid arthritis bone destruction.
LIN Y J , ANZAGHE M , STEFAN S . Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis [J]. Cells , 2020 , 9 ( 4 ): 880 .
LITTLEJOHN E A , MONRAD S U . Early diagnosis and treatment of rheumatoid arthritis [J]. Prim Care , 2018 , 45 ( 2 ): 237 - 255 .
DEANE K D , DEMORUELLE M K , KELMENSON L B , et al . Genetic and environmental risk factors for rheumatoid arthritis [J]. Best Pract Res Clin Rheumatol , 2017 , 31 ( 1 ): 3 - 18 .
中华医学会风湿病学分会 . 2018中国类风湿关节炎诊疗指南 [J]. 中华内科杂志 , 2018 , 57 ( 4 ): 242 - 251 .
SMOLEN J S , ALETAHA D , MCINNES I B . Rheumatoid arthritis [J]. The Lancet , 2016 , 388 ( 10055 ): 2023 - 2038 .
XIAO Q , LI X , LI Y , et al . Biological drug and drug delivery-mediated immunotherapy [J]. Acta Pharm Sin B , 2021 , 11 ( 4 ): 941 - 960 .
中华医学会风湿病学分会 . 类风湿关节炎诊断及治疗指南 [J]. 中华风湿病学杂志 , 2010 , 14 ( 4 ): 265 - 270 .
中华中医药学会风湿病分会 . 类风湿关节炎病证结合诊疗指南 [J]. 中医杂志 , 2018 , 59 ( 20 ): 1794 - 1800 .
郑筱萸 . 中药新药临床研究指导原则(试行) [M]. 北京 : 中国医药科技出版社 , 2002 : 116 - 119 .
展俊平 , 谷慧敏 , 孟庆良 , 等 . 虎潜丸加减治疗类风湿关节炎肝肾阴虚证的临床观察 [J]. 中国实验方剂学杂志 , 2019 , 25 ( 1 ): 107 - 113 .
WELLS G , BECKER J C , TENG J , et al . Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate [J]. Ann Rheum Dis , 2009 , 68 ( 6 ): 954 - 960 .
李平顺 , 王钢 , 周孟茹 . 基于RANKL-RANK-OPG环路探讨骨痨愈康丸改善肝肾亏虚型类风湿关节炎患者骨破坏机制研究 [J]. 中华中医药杂志 , 2020 , 35 ( 3 ): 1603 - 1607 .
姜泉 , 蒋红 , 曹炜 , 等 . 475例类风湿关节炎患者中医临床证候分析 [J]. 中医杂志 , 2007 , 48 ( 3 ): 253 - 255 .
何奕坤 , 沈佳莹 , 吴凡 , 等 . 早期类风湿关节炎中医辨证分型与肌骨超声表现相关性研究 [J]. 中国中医药信息杂志 , 2022 , 29 ( 2 ): 115 - 119 .
庄红艳 , 房萌 , 王艳梅 , 等 . 苍术防治疫病本草文献、药理学及临床研究概况 [J]. 中国药业 , 2020 , 29 ( 21 ): 1 - 4 .
雍晨 , 鲁璐 , 汪悦 . 基于网络药理学研究土茯苓的活性成分及药理机制 [J]. 辽宁中医杂志 , 2019 , 46 ( 9 ): 1926 - 1930
王甲任 , 顾留歌 , 秦燕 . 基于网络药理学及分子对接研究穿心莲抗炎的分子机制 [J]. 中国医药工业杂志 , 2021 , 52 ( 4 ): 519 - 533
郭思琦 , 姜春燕 , 张百霞 . 基于网络药理学的忍冬藤抗类风湿关节炎作用机制研究 [J]. 世界科学技术—中医药现代化 , 2020 , 22 ( 5 ): 1716 - 1724 .
秦慧真 , 林思 , 邓玲玉 , 等 . 穿心莲内酯药理作用及机制研究进展 [J]. 中国实验方剂学杂志 , 2022 , 28 ( 6 ): 272 - 282 .
ZHAO H , LU A , HE X . Roles of microRNAs in bone destruction of rheumatoid arthritis [J]. Front Cell Dev Biol , 2020 , doi: 10.3389/fcell.2020.600867 http://dx.doi.org/10.3389/fcell.2020.600867 .
NAKASHIMA T , HAYASHI M , TAKAYANAGI H . New insights into osteoclastogenic signaling mechanisms [J]. Trends Endocrinol Metab , 2012 , 23 ( 11 ): 582 - 590 .
OKAMOTO K , NAKASHIMA T , SHINOHARA M , et al . Osteoimmunology: The conceptual framework unifying the immune and skeletal systems [J]. Physiol Rev , 2017 , 97 ( 4 ): 1295 - 1349 .
JIMI E , AKIYAMA S , TSURUKAI T , et al . Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function [J]. J Immunol , 1999 , 163 ( 1 ): 434 - 442 .
BLAIR J M , ZHENG Y , DUNSTAN C R . RANK ligand [J]. Int J Biochem Cell Biol , 2007 , 39 ( 6 ): 1077 - 1081 .
KONG Y Y , YOSHIDA H , SAROSI I , et al . OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis [J]. Nature , 1999 , 397 ( 6717 ): 315 - 323 .
DOUGALL W C , GLACCUM M , CHARRIER K , et al . RANK is essential for osteoclast and lymph node development [J]. Genes Dev , 1999 , 13 ( 18 ): 2412 - 2424 .
LI J , SAROSI I , YAN X Q , et al . RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism [J]. Proc Natl Acad Sci U S A , 2000 , 97 ( 4 ): 1566 - 1571 .
UDAGAWA N , KOIDE M , NAKAMURA M , et al . Osteoclast differentiation by RANKL and OPG signaling pathways [J]. J Bone Miner Metab , 2021 , 39 ( 1 ): 19 - 26 .
WEI S T , SUN Y H , ZONG S H , et al . Serum levels of IL-6 and TNF- α may correlate with activity and severity of rheumatoid arthritis [J]. Med Sci Monit , 2015 , 21 : 4030 - 4038 .
JUNG S M , KIM K W , YANG C W , et al . Cytokine-mediated bone destruction in rheumatoid arthritis [J]. J Immunol Res , 2014 , doi: 10.1155/2014/263625 http://dx.doi.org/10.1155/2014/263625 .
ABBAS S , ZHANG Y H , CLOHISY J C , et al . Tumor necrosis factor-alpha inhibits pre-osteoblast differentiation through its type-1 receptor [J]. Cytokine , 2003 , 22 ( 1/2 ): 33 - 41 .
GILBERT L C , RUBIN J , NANES M S . The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis [J]. Am J Physiol Endocrinol Metab , 2005 , 288 ( 5 ): E1011 - E1018 .
DARRIEUTORT-LAFFITE C , BOUTET M A , CHATELAIS M , et al . IL-1 β and TNF- α promote monocyte viability through the induction of GM-CSF expression by rheumatoid arthritis synovial fibroblasts [J]. Mediators Inflamm , 2014 , 2014 ( 1 ): 241840 .
WANG Y , GAO W . Effects of TNF- α on autophagy of rheumatoid arthritis fibroblast-like synoviocytes and regulation of the NF- κ B signaling pathway [J]. Immunobiology , 2021 , 226 ( 2 ): 152059 .
YOKOTAK K , SATO K , MIYAZAKI T , et al . Characterization and function of tumor necrosis factor and interleukin-6-induced osteoclasts in rheumatoid arthritis [J]. Arthritis Rheumatol , 2021 , 73 ( 7 ): 1145 - 1154 .
0
Views
27
下载量
1
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution